Contact
searchSearch
HMP Global

Lymphoma, Leukemia & Myeloma Network

Featured

Olalekan Oluwole, MD, MBBS
Conference Coverage
Time and Travel Impact of CAR T-Cell vs Bispecific Antibody Therapy for Patients With R/R DLBCL: Real-World Analysis
01/26/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS,...
01/26/2026
Oncology
From Oncology
Bilal Abid MD, MS, FACP, MRCP, FRCP
Conference Coverage
Evaluating Infection Patterns Among Patients With Multiple Myeloma Receiving BCMA-Targeting CAR T-Cell Therapy
01/26/2026
Bilal Abid, MD, MS, FACP, MRCP, FRCP
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP,...
01/26/2026
Oncology
From Oncology
Matthew Connor, MD
Conference Coverage
Evolving Strategies for the Treatment of Acute Lymphoblastic Leukemia
01/22/2026
Matthew Connor, MD
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted...
01/22/2026
Oncology
From Oncology
Ira Zackon, MD
Conference Coverage
Real-World Analysis Shows Rapid Uptake of Bispecific Antibodies in Community Settings for Multiple Myeloma Treatment
01/22/2026
Ira Zackon, MD
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results...
01/22/2026
Oncology
From Oncology
Saad Usmani, MD, MBA, FACP, FASCO
Conference Coverage
KTX1001 Monotherapy Shows Clinical Activity and Manageable Safety for R/R Myeloma
01/22/2026
Saad Usmani, MD, MBA, FACP, FASCO
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP,...
01/22/2026
Oncology
From Oncology
Ola Landgren, MD, PhD
Conference Coverage
Daratumumab Plus Teclistamab Demonstrates Favorable Safety and Efficacy for Smoldering Multiple Myeloma: REVIVE Study
01/22/2026
C. Ola Landgren, MD, PhD
Ola Landgren, MD, PhD, shared early results from the phase 2 REVIVE study which showed daratumumab plus teclistamab can be safely administered for high-risk smoldering myeloma.
Ola Landgren, MD, PhD, shared early results from the phase 2 REVIVE study which showed daratumumab plus teclistamab can be safely administered for high-risk smoldering myeloma.
Ola Landgren, MD, PhD, shared...
01/22/2026
Oncology
From Oncology
Jeff Sharman, MD
Conference Coverage
Mosunetuzumab Demonstrates Strong Efficacy for Elderly Patients With Diffuse Large B-Cell Lymphoma
01/22/2026
Jeff P. Sharman
Jeff Sharman, MD, reported phase 2 results that showed frontline mosunetuzumab therapy produced high response rates with minimal toxicity among elderly, treatment-naive patients with DLBCL who were unfit for standard chemotherapy.
Jeff Sharman, MD, reported phase 2 results that showed frontline mosunetuzumab therapy produced high response rates with minimal toxicity among elderly, treatment-naive patients with DLBCL who were unfit for standard chemotherapy.
Jeff Sharman, MD, reported phase...
01/22/2026
Oncology
From Oncology
News
FDA Issues Draft Guidance on Use of MRD and Complete Response as End Points to Support Accelerated Approval in Multiple Myeloma
01/20/2026
Emily Estrada
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA...
01/20/2026
Oncology
From Oncology
Julia Han Noll, PhD
Conference Coverage
Mechanistic Insights Into Delayed Immune Toxicities Following BCMA CAR T-Cell Therapy
01/16/2026
Julia Han Noll, PhD
Julia Han Noll, PhD, University of Pennsylvania, Philadelphia, Pennsylvania, presented mechanistic data identifying a distinct spectrum of delayed toxicities associated with BCMA-directed CAR T-cell therapy at the 2025 ASH Annual Meeting &...
Julia Han Noll, PhD, University of Pennsylvania, Philadelphia, Pennsylvania, presented mechanistic data identifying a distinct spectrum of delayed toxicities associated with BCMA-directed CAR T-cell therapy at the 2025 ASH Annual Meeting &...
Julia Han Noll, PhD, University...
01/16/2026
Oncology
From Oncology
Matthew Connor, MD
Conference Coverage
IL18-Armored CAR T-Cell Therapy Produces Deep and Sustained Responses for Heavily Pretreated B-Cell Acute Lymphoblastic Leukemia
01/16/2026
Matthew Connor, MD
Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.
Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.
Matthew Connor, MD, reported...
01/16/2026
Oncology
From Oncology
Krish Patel, MD
Conference Coverage
Analyzing Patient Preferences on Follicular Lymphoma Treatment Delivery Options
01/16/2026
Krish Patel, MD
Krish Patel, MD, shared results from a patient preference study for relapsed/refractory follicular lymphoma at the 2025 ASH Annual Meeting & Exposition.
Krish Patel, MD, shared results from a patient preference study for relapsed/refractory follicular lymphoma at the 2025 ASH Annual Meeting & Exposition.
Krish Patel, MD, shared results...
01/16/2026
Oncology
From Oncology

Interactive Features

Quiz
Rovadicitinib for Ruxolitinib-Resistant or Intolerant Myelofibrosis
01/14/2026
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The...
01/14/2026
Oncology
Quiz
Chidamide Plus Azacitidine Maintenance Therapy for AML
01/12/2026
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following...
01/12/2026
Oncology
Quiz
CAR T-Cell Therapies and Survival Outcomes Among Patients With R/R FL
12/03/2025
True or False: According to results from a comparative analysis, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, demonstrated superior survival outcomes among patients with R/R...
True or False: According to results from a comparative analysis, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, demonstrated superior survival outcomes among patients with R/R...
True or False: According to...
12/03/2025
Oncology
Quiz
Enasidenib Plus Venetoclax for IDH2-Mutant AML
12/01/2025
True or False: According to results from the ENAVEN-AML trial, the combination of enasidenib and venetoclax showed encouraging clinical activity and a manageable safety profile among patients with R/R acute myeloid leukemia and an IDH2...
True or False: According to results from the ENAVEN-AML trial, the combination of enasidenib and venetoclax showed encouraging clinical activity and a manageable safety profile among patients with R/R acute myeloid leukemia and an IDH2...
True or False: According to...
12/01/2025
Oncology
Quiz
Polatuzumab-Based Therapy for R/R DLBCL
12/01/2025
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab vedotin combined with rituximab and bendamustine demonstrated inferior overall survival compared with conventional chemotherapy among patients with R/R diffuse large B-cell lymphoma.
True or False: Polatuzumab...
12/01/2025
Oncology
Quiz
Pelabresib Plus Ruxolitinib for Myelofibrosis
12/01/2025
True or False: The combination of pelabresib and ruxolitinib, compared with ruxolitinib alone, demonstrated negative clinical efficacy and increased symptom burden among patients with myelofibrosis in the phase 3 MANIFEST-2 trial.
True or False: The combination of pelabresib and ruxolitinib, compared with ruxolitinib alone, demonstrated negative clinical efficacy and increased symptom burden among patients with myelofibrosis in the phase 3 MANIFEST-2 trial.
True or False: The combination...
12/01/2025
Oncology
Quiz
Relmacabtagene Autoleucel for R/R Follicular Lymphoma
10/30/2025
Emily Estrada
True or False: Among heavily pretreated patients with R/R follicular lymphoma, relmacabtagene autoleucel demonstrated deep and durable responses with a favorable safety profile, according to results from the phase 2 RELIANCE study.
True or False: Among heavily pretreated patients with R/R follicular lymphoma, relmacabtagene autoleucel demonstrated deep and durable responses with a favorable safety profile, according to results from the phase 2 RELIANCE study.
True or False: Among heavily...
10/30/2025
Oncology
Quiz
Daratumumab for High-Risk Smoldering Multiple Myeloma
10/30/2025
Emily Estrada
True or False: According to results from the phase 3 AQUILA study, fixed-duration subcutaneous daratumumab significantly prolonged PFS and delayed treatment initiation compared with active monitoring for patients with high-risk smoldering MM.
True or False: According to results from the phase 3 AQUILA study, fixed-duration subcutaneous daratumumab significantly prolonged PFS and delayed treatment initiation compared with active monitoring for patients with high-risk smoldering MM.
True or False: According to...
10/30/2025
Oncology
Quiz
Venetoclax Plus Azacitidine for Relapsed AML
10/30/2025
Emily Estrada
True or False: Venetoclax combined with azacitidine demonstrated poor clinical responses with unmanageable toxicity for elderly patients with relapsed acute myeloid leukemia, based on results from a single-center retrospective study.
True or False: Venetoclax combined with azacitidine demonstrated poor clinical responses with unmanageable toxicity for elderly patients with relapsed acute myeloid leukemia, based on results from a single-center retrospective study.
True or False: Venetoclax...
10/30/2025
Oncology
Quiz
Clarithromycin-Based Quadruplet Therapy for R/R MM
10/24/2025
True or False: For patients with R/R multiple myeloma, including those with high-risk cytogenetics, an all-oral combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated high response rates and prolonged...
True or False: For patients with R/R multiple myeloma, including those with high-risk cytogenetics, an all-oral combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated high response rates and prolonged...
True or False: For patients with...
10/24/2025
Oncology

Insights

Olalekan Oluwole, MD, MBBS
Conference Coverage
Time and Travel Impact of CAR T-Cell vs Bispecific Antibody Therapy for Patients With R/R DLBCL: Real-World Analysis
01/26/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS,...
01/26/2026
Oncology
Bilal Abid MD, MS, FACP, MRCP, FRCP
Conference Coverage
Evaluating Infection Patterns Among Patients With Multiple Myeloma Receiving BCMA-Targeting CAR T-Cell Therapy
01/26/2026
Bilal Abid, MD, MS, FACP, MRCP, FRCP
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP,...
01/26/2026
Oncology
Matthew Connor, MD
Conference Coverage
Evolving Strategies for the Treatment of Acute Lymphoblastic Leukemia
01/22/2026
Matthew Connor, MD
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted...
01/22/2026
Oncology
Ira Zackon, MD
Conference Coverage
Real-World Analysis Shows Rapid Uptake of Bispecific Antibodies in Community Settings for Multiple Myeloma Treatment
01/22/2026
Ira Zackon, MD
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results...
01/22/2026
Oncology
Saad Usmani, MD, MBA, FACP, FASCO
Conference Coverage
KTX1001 Monotherapy Shows Clinical Activity and Manageable Safety for R/R Myeloma
01/22/2026
Saad Usmani, MD, MBA, FACP, FASCO
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP,...
01/22/2026
Oncology
Ola Landgren, MD, PhD
Conference Coverage
Daratumumab Plus Teclistamab Demonstrates Favorable Safety and Efficacy for Smoldering Multiple Myeloma: REVIVE Study
01/22/2026
C. Ola Landgren, MD, PhD
Ola Landgren, MD, PhD, shared early results from the phase 2 REVIVE study which showed daratumumab plus teclistamab can be safely administered for high-risk smoldering myeloma.
Ola Landgren, MD, PhD, shared early results from the phase 2 REVIVE study which showed daratumumab plus teclistamab can be safely administered for high-risk smoldering myeloma.
Ola Landgren, MD, PhD, shared...
01/22/2026
Oncology
Jeff Sharman, MD
Conference Coverage
Mosunetuzumab Demonstrates Strong Efficacy for Elderly Patients With Diffuse Large B-Cell Lymphoma
01/22/2026
Jeff P. Sharman
Jeff Sharman, MD, reported phase 2 results that showed frontline mosunetuzumab therapy produced high response rates with minimal toxicity among elderly, treatment-naive patients with DLBCL who were unfit for standard chemotherapy.
Jeff Sharman, MD, reported phase 2 results that showed frontline mosunetuzumab therapy produced high response rates with minimal toxicity among elderly, treatment-naive patients with DLBCL who were unfit for standard chemotherapy.
Jeff Sharman, MD, reported phase...
01/22/2026
Oncology
Julia Han Noll, PhD
Conference Coverage
Mechanistic Insights Into Delayed Immune Toxicities Following BCMA CAR T-Cell Therapy
01/16/2026
Julia Han Noll, PhD
Julia Han Noll, PhD, University of Pennsylvania, Philadelphia, Pennsylvania, presented mechanistic data identifying a distinct spectrum of delayed toxicities associated with BCMA-directed CAR T-cell therapy at the 2025 ASH Annual Meeting &...
Julia Han Noll, PhD, University of Pennsylvania, Philadelphia, Pennsylvania, presented mechanistic data identifying a distinct spectrum of delayed toxicities associated with BCMA-directed CAR T-cell therapy at the 2025 ASH Annual Meeting &...
Julia Han Noll, PhD, University...
01/16/2026
Oncology
Matthew Connor, MD
Conference Coverage
IL18-Armored CAR T-Cell Therapy Produces Deep and Sustained Responses for Heavily Pretreated B-Cell Acute Lymphoblastic Leukemia
01/16/2026
Matthew Connor, MD
Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.
Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.
Matthew Connor, MD, reported...
01/16/2026
Oncology
Krish Patel, MD
Conference Coverage
Analyzing Patient Preferences on Follicular Lymphoma Treatment Delivery Options
01/16/2026
Krish Patel, MD
Krish Patel, MD, shared results from a patient preference study for relapsed/refractory follicular lymphoma at the 2025 ASH Annual Meeting & Exposition.
Krish Patel, MD, shared results from a patient preference study for relapsed/refractory follicular lymphoma at the 2025 ASH Annual Meeting & Exposition.
Krish Patel, MD, shared results...
01/16/2026
Oncology

Meeting Materials

In the News

News
FDA Issues Draft Guidance on Use of MRD and Complete Response as End Points to Support Accelerated Approval in Multiple Myeloma
01/20/2026
Emily Estrada
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA...
01/20/2026
Oncology
News
Oral Iberdomide Combination Demonstrates Clinically Meaningful Activity for R/R Multiple Myeloma
01/14/2026
Emily Estrada
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of...
01/14/2026
Oncology
News
High Non-Relapse Mortality Remains Barrier to Allogeneic Transplantation Success Rates for Patients With Myelofibrosis
01/14/2026
Emily Estrada
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with...
01/14/2026
Oncology
News
Pacritinib Therapy Shows Improved Symptom Reduction and Spleen Response for Patients With Myelofibrosis and Thrombocytopenia
01/14/2026
Emily Estrada
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed...
01/14/2026
Oncology
News
Decitabine Plus Cedazuridine Maintenance Therapy Shows Promising Survival Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndromes
01/12/2026
Emily Estrada
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine...
01/12/2026
Oncology
News
Venetoclax Plus CACAG Regimen Demonstrates High Response Rates and Favorable Survival for R/R Acute Myeloid Leukemia
01/12/2026
Emily Estrada
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax...
01/12/2026
Oncology
Conference Coverage
Tabelecleucel Shows Activity and Favorable Safety for Pediatric Patients With R/R EBV-Positive Post-Transplant Lymphoproliferative Disease: ALLELE Trial
12/29/2025
Emily Estrada
Tabelecleucel demonstrated durable responses and favorable safety among pediatric patients with relapsed/refractory Epstein–Barr virus-positive PTLD, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Tabelecleucel demonstrated durable responses and favorable safety among pediatric patients with relapsed/refractory Epstein–Barr virus-positive PTLD, according to results presented at the 2025 ASH Annual Meeting & Exposition.
Tabelecleucel demonstrated...
12/29/2025
Oncology
Conference Coverage
Real-World ctDNA Monitoring Shows MRD Clearance Predicts Relapse Risk and Survival Outcomes for DLBCL: HOVON-902 Analysis
12/11/2025
Emily Estrada
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring among patients with DLBCL may predict relapse risk and survival outcomes, according to real-world study results presented at the 2025 ASH Annual Meeting & Exposition.
Serial ctDNA MRD monitoring...
12/11/2025
Oncology
Conference Coverage
Outcomes of Cilta-Cel Manufacturing for Lenalidomide-Refractory Multiple Myeloma Strongly Influenced by Prior Lines of Therapy
12/06/2025
Emily Estrada
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene...
12/06/2025
Oncology
Conference Coverage
Talquetamab Plus Teclistamab Demonstrates Durable Efficacy for Patients With R/R MM and Extramedullary Disease: Updated Results from RedirecTT-1 Study
12/06/2025
Emily Estrada
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab...
12/06/2025
Oncology

Latest Podcasts

Podcasts
Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress
10/19/2020
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what...
10/19/2020
Oncology
Podcasts
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
08/24/2020
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an...
08/24/2020
Oncology
Podcasts
Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population
06/19/2018
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new...
06/19/2018
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use